DALY II USA/ MB-CART2019.1 for DLBCL | MicrobiomeTrials← Back to trialsNCT04792489
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2021-05-25Est. Completion: 2026-12-31
Enrollment target: 315 participants Locations- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Mayo Clinic, Phoenix, Arizona, United States
- UC San Diego Health, La Jolla, California, United States
- Stanford University, Stanford, California, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Yale University, New Haven, Connecticut, United States
- Baptist Health Miami Cancer Institute, Miami, Florida, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
- Robert H Lurie Cancer Center, Chicago, Illinois, United States
- University of Kansas Cancer Center, Westwood, Kansas, United States
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
Other microbiome trials you might be interested in
Diffuse Large B-Cell Lymphoma (DLBCL)Hodgkin LymphomaPeripheral T-cell Lymphoma (PTCL)Anaplastic Large Cell Lymphoma, ALK-PositiveAnaplastic Large Cell Lymphoma, ALK-Negative
This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express …
Houston, United StatesEst. completion Mar 31, 2030
B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell Lymphoma
Mayo Clinic, Rochester, Minnesota, United StatesWashington University, St. Louis, St Louis, Missouri, United StatesUniversity of Nebraska Medical Center, Omaha, Nebraska, United StatesMemorial Sloan Kettering Cancer Center, New York, New York, United StatesDuke University Medical Center - Division of Hematologic Malignancies, Durham, North Carolina, United StatesThe Ohio State University Wexner Medical Center James Cancer, Columbus, Ohio, United StatesOregon Health and Science University Knight Cancer Institute, Portland, Oregon, United StatesAllegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, United StatesUniversity of Pittsburgh - Hillman Cancer Center, Pittsburgh, Pennsylvania, United StatesSCRI Oncology Partners, Nashville, Tennessee, United StatesUT Southwestern Medical Center, Dallas, Texas, United StatesThe University of Texas MD Anderson Cancer Center, Houston, Texas, United StatesTexas Transplant Institute, San Antonio, Texas, United StatesFred Hutchinson Cancer Center, Seattle, Washington, United StatesFroedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United StatesUniversity of Alberta Cross Cancer Institute, Edmonton, Alberta, CanadaPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaBurkitt Lymphoma
Neuroblastoma
Ewing Sarcoma
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…
Los Angeles, United StatesEst. completion Mar 31, 2029
Hematologic Cancer
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood …
Tucson, United StatesEst. completion Mar 2031